Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | HEXA | P06865 | 1/20 | 0.53 |
| ▸ | HEXB | P07686 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | DRD2 | P14416 | 4/20 | 0.51 |
| ▸ | HTR6 | P50406 | 4/20 | 0.51 |
| ▸ | MAOB | P27338 | 4/20 | 0.51 |
| ▸ | HTR1A | P08908 | 3/20 | 0.51 |
| ▸ | HTR2A | P28223 | 3/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.51 |
| ▸ | HRH1 | P35367 | 3/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2743018 | 0.86 | HPGD (0.61) | HPGDNPSR1RAB9ANPC1TSHR | |
| SCHEMBL7519591 | 0.84 | GAA (0.60) | HPGDNPSR1RAB9ANPC1TSHR | |
| SCHEMBL8862746 | 0.84 | GAA (0.60) | HPGDNPSR1RAB9ANPC1TSHR | |
| SCHEMBL8862940 | 0.84 | GAA (0.60) | HPGDNPSR1RAB9ANPC1TSHR | |
| SCHEMBL8862856 | 0.84 | GAA (0.60) | HPGDNPSR1RAB9ANPC1TSHR | |
| SCHEMBL17354801 | 0.84 | MAOB (0.49) | HPGDNPSR1RAB9AMAOBNPC1 | |
| SCHEMBL21459052 | 0.83 | MAOB (0.51) | HPGDNPSR1MAOBKMT2A | |
| SCHEMBL30839875 | 0.83 | HEXA (0.72) | HEXAHEXBDRD2HTR6MAOB | |
| SCHEMBL13590076 | 0.83 | HEXA (0.72) | HEXAHEXBDRD2HTR6MAOB | |
| SCHEMBL30274276 | 0.82 | MAOB (0.47) | HPGDNPSR1RAB9AMAOBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3898631-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| EP-3898629-B1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| EP-3898630-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3897839-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| CN-113226469-A | Imidazopyrazine derivatives as antibacterial agents | 豪夫迈·罗氏有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-113195496-A | Imidazopyrazine derivatives as antibacterial agents | 豪夫迈·罗氏有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-113195498-A | Novel imidazopyrazine derivatives | 豪夫迈·罗氏有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-113195497-A | Novel imidazopyrazine derivatives | 豪夫迈·罗氏有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-113164771-A | Imidazopyrazine derivatives as antibacterial agents | 豪夫迈·罗氏有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020126954-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020127075-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020126953-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020126956-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020126952-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | HPGD 2220/4885NPSR1 2685/4885HEXA 4253/4885 |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | HPGD 2220/4885NPSR1 2685/4885HEXA 4253/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | HPGD 2260/4885NPSR1 2703/4885HEXA 4294/4885 |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IL4, RPS4Y1, RPS4X | HPGD 2459/4885NPSR1 3026/4885HEXA 4225/4885 |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, MYD88, IL1R1 | HPGD 2363/4885NPSR1 2667/4885HEXA 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.